Hybrid AI/ML-mechanistic framework enables intelligent optimization of commercial biopharmaceutical downstream processing

混合人工智能/机器学习机制框架可实现商业生物制药下游工艺的智能优化

阅读:2

Abstract

Biopharmaceutical manufacturing requires continuous improvement to ensure robust, efficient, and high-quality processes, yet traditional experimental designs remain resource-demanding and insufficient to capture interactions of multiple parameters. Here, we introduce a hybrid framework integrating artificial intelligence (AI)/machine learning (ML) with mechanistic modeling to optimize anion-exchange chromatography and resolve the long-standing yield-purity trade-off in PEGylated protein purification. Three critical process parameters were first identified through correlation analysis between 30 input factors and critical quality attributes/process yield from 400+ commercial manufacturing lots, which were further refined using equilibrium dispersive and steric mass action models. Over 40,000 in silico optimization via the mechanistic model resolved the yield-purity trade-off, achieving a 12% increase in yield and 33% reduction in high-molecular-weight impurities. The optimized process conditions were verified across laboratory (n = 3), pilot (n = 3), and commercial (n = 18) runs, consistently demonstrating scalability and process robustness. This study highlights the power of combining data-driven machine learning with mechanistic modeling for process optimization, leading to an improved commercial process with substantial cost savings and paving the way for upcoming intelligent biomanufacturing.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。